Are Analysts Bullish about Five Prime Therapeutics Inc (NASDAQ:FPRX) after last week?

June 19, 2017 - By Louis Casey

 Are Analysts Bullish about Five Prime Therapeutics Inc (NASDAQ:FPRX) after last week?
Investors sentiment decreased to 0.74 in Q4 2016. Its down 0.41, from 1.15 in 2016Q3. It worsened, as 19 investors sold Five Prime Therapeutics Inc shares while 69 reduced holdings. 16 funds opened positions while 49 raised stakes. 24.63 million shares or 4.67% less from 25.83 million shares in 2016Q3 were reported.
American Century Inc has invested 0% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Martingale Asset Management Ltd Partnership reported 11,506 shares. 17,400 were accumulated by Qs Ltd Liability Corporation. Weiss Multi accumulated 0.07% or 28,000 shares. Voya Inv Mgmt Ltd Com reported 11,497 shares. Sei Investments Commerce has invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Nationwide Fund Advisors has invested 0.01% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Deutsche Commercial Bank Ag owns 92,634 shares. Perceptive Lc owns 163,255 shares or 0.58% of their US portfolio. Adage Prtnrs Ltd Liability reported 0.26% in Five Prime Therapeutics Inc (NASDAQ:FPRX). New Jersey-based Blackrock Investment Mgmt Ltd Liability has invested 0.01% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Alliancebernstein Limited Partnership holds 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX) or 89,550 shares. Wcm Inv Mgmt Ca holds 14,330 shares or 0.01% of its portfolio. The Illinois-based First Tru Advsr Lp has invested 0.01% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Gsa Partners Llp invested in 0.22% or 72,279 shares.

Since December 23, 2016, it had 0 buys, and 4 sales for $1.73 million activity. RINGO WILLIAM R also sold $23,365 worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) on Wednesday, March 1. Sarena Francis Willard also sold $172,310 worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) on Wednesday, January 18. Shares for $1.51M were sold by Williams Lewis T on Friday, December 23.

Five Prime Therapeutics Inc (NASDAQ:FPRX) Ratings Coverage

Among 7 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Five Prime Therapeutics had 11 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Credit Suisse on Thursday, January 21. On Tuesday, April 12 the stock rating was initiated by BMO Capital Markets with “Market Perform”. Citigroup initiated the shares of FPRX in report on Tuesday, October 25 with “Buy” rating. The company was maintained on Monday, October 19 by Oppenheimer. The rating was maintained by Credit Suisse with “Outperform” on Friday, March 11. The firm has “Outperform” rating by Wells Fargo given on Friday, December 4. The stock has “Buy” rating by Citigroup on Friday, July 31. The firm has “Sell” rating given on Tuesday, August 11 by Zacks. Zacks upgraded the stock to “Sell” rating in Friday, August 21 report. Below is a list of Five Prime Therapeutics Inc (NASDAQ:FPRX) latest ratings and price target changes.

24/03/2017 Broker: Cowen & Co Rating: Outperform Initiates Coverage On
02/03/2017 Broker: Nomura Rating: Buy Initiates Coverage On

About 32,759 shares traded. Five Prime Therapeutics Inc (NASDAQ:FPRX) has declined 30.56% since June 19, 2016 and is downtrending. It has underperformed by 47.26% the S&P500.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The company has market cap of $830.93 million. The Company’s product candidates include Cabiralizumab , which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. It currently has negative earnings.

More notable recent Five Prime Therapeutics Inc (NASDAQ:FPRX) news were published by: Reuters.com which released: “BRIEF-Protagonist Therapeutics appoints Five Prime Therapeutics CEO to board …” on June 08, 2017, also Globenewswire.com with their article: “Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single …” published on June 03, 2017, Streetinsider.com published: “Five Prime Therapeutics (FPRX) Announces Updated Data From Phase 1 Trial of …” on June 03, 2017. More interesting news about Five Prime Therapeutics Inc (NASDAQ:FPRX) were released by: Nasdaq.com and their article: “Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 …” published on June 04, 2017 as well as Seekingalpha.com‘s news article titled: “Five Prime Therapeutics At An Attractive Entry Level” with publication date: May 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.